Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

Delayed Quote. Delayed  - 08/26 10:02:00 pm
0.5386 USD   +1.55%
08/11 NAVIDEA BIOPHAR : Announces 2016 Annual Meeting Results
08/08 NAVIDEA BIOPHAR : Executes a Term Sheet with Cerveau Technologies to..
08/04 NAVIDEA BIOPHAR : reports 2Q loss
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
08/22/2016 08/23/2016 08/24/2016 08/25/2016 08/26/2016 Date
0.5397(c) 0.5401(c) 0.5389(c) 0.5304(c) 0.5386(c) Last
320 368 613 222 152 148 193 567 187 241 Volume
+7.34% +0.07% -0.22% -1.58% +1.55% Change
More quotes
Financials ($)
Sales 2016 24,7 M
EBIT 2016 -4,56 M
Net income 2016 -12,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 35,9 M
EBIT 2017 4,69 M
Net income 2017 -4,41 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 3,39x
Capi. / Sales2017 2,34x
Capitalization 83,9 M
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
08/18 NAVIDEA BIOPHARMACEUTICALS : Executes a Term Sheet with Cerveau Technologies to ..
08/11 NAVIDEA BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security H..
08/11 NAVIDEA BIOPHARMACEUTICALS : Announces 2016 Annual Meeting Results
08/11 NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
08/08 NAVIDEA BIOPHARMACEUTICALS : Executes a Term Sheet with Cerveau Technologies to ..
08/04 NAVIDEA BIOPHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results o..
08/04 NAVIDEA BIOPHARMACEUTICALS : reports 2Q loss
08/04 NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
08/04 NAVIDEA BIOPHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
07/28 NAVIDEA BIOPHARMACEUTICALS : Receives IRB Approval for its Lymphoseek® Rheumatoi..
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/05 Navidea Biopharmaceuticals (NAVB) Q2 2016 Results - Earnings Call Transcript
08/04 Navidea Biopharm misses by $0.01, beats on revenue
06/14 Navidea to update investors tomorrow on CRG litigation
05/24 Financier says Navidea in default on loan, tries to seize company's accounts
05/17 Navidea Biopharmaceuticals' (NAVB) Management on Q1 2016 Results - Earnings C..
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg Chairman
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-59.50%84
INCYTE CORPORATION-25.27%15 236
CELLTRION, INC.--.--%11 367
LONZA GROUP AG14.78%10 130
QUINTILES TRANSNATIONA..10.24%8 968
ALKERMES PLC-43.94%6 744
More Results